<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200922048806N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-30</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of an Education on treatment adherence and readmition in  Patients with heart failure</public_title>
      <acronym></acronym>
      <scientific_title>The effect of an Educational Intervention Based on PRECEDE – PROCEED Model on treatment adherence and readmition rate among Patients with heart failure</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51489</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: A total of 72 samples are selected based on the inclusion criteria and by  convenience sampling method, and are allocated to the control and intervention groups using block random allocation method.. Depending on the sample size, 18 blocks of 4 are required for random block allocation. The intervention group will be displayed with A and the control group with B. Samples can be placed in blocks in 6 different modes. The website https://www.Randomization.com will be used to determine the random sequence of blocks. In order to allocation concealment from the researcher, 72 dark envelopes were prepared and each of the random sequences created was recorded on a card and placed inside the envelope, and finally the envelope lid was pasted. At the beginning of the registration of individuals, according to the order of arrival of the samples, one of the envelopes is opened in order and the assigned group of that sample is specified.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Heart Failure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The educational intervention is designed based on the third phase of the Precede- Proceed Model, educational assessment, among the predisposing, enabling, and reinforcing constructs. Then, impact evaluation is carried out to examine the immediate effect of the program, including therapy adherence and readmission. Predisposing factors include the knowledge, attitudes, and beliefs of the affected person. Two 60-minute face-to-face sessions will be held to promote patients' awareness. In the first training session, we will discuss the following themes: familiarity of patients with adherence to treatment and medication, their knowledge about the benefits of treatment adherence and how to use medication, the definition of adherence to medication and therapy, and factors affecting these variables, appropriate dietary and lifestyle changes in heart failure according to the existing recommendations, and approaches to control these variables. There will be two 60-minute discussion sessions to assess patients' attitudes and provide the researcher's opinion to the participants. Reinforcing factors in this study include encouragement from the spouse or a family member (a key figure in a person's life). A 60-minute face-to-face meeting will be held with the key person to discuss the family's role in the disease process, encouragement strategies, and methods to motivate the patient. The enabling factors include two 60-minute training sessions to discuss the role of mass media in treatment adherence and the importance of quality of life improvement. Also, the authors will use a virtual social network. Finally, there will be a session to review the issues and resolve the problems and any ambiguities. Researchers will use PowerPoint slides and educational posters in all sessions. The intervention is performed for the experimental group in a month (two sessions per week). During this time, the intervention group will join a virtual educational channel, and the educational materials will be shared in this channel. Before and after the intervention, a demographic questionnaire, the Madanloo treatment adherence questionnaire, and a researcher-made readmission inventory will be completed. Post-test will be conducted one and three months after training, respectively. Intervention 2: Control group: The control group will not receive any intervention and receive routine care.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereshte Eskandari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam khomaini Hospital., Sepah ave., Parastar Blvd., Dehdasht., Yasouj</address>
        <city>Dehdasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7571888655</zip>
        <telephone>+98 74 3226 5904</telephone>
        <email>8238fereshte.eskandari@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahrzad Pashahipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing Midwifery ,Tehran University of Medical Sciences., Nosrat st., Tohid sq., TEHRAN., IRAN</address>
        <city>Theran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6105 4142</telephone>
        <email>sh-pashaeipour@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>History of hospitalization at least once
Have at least one year of heart failure
Have Class II (mild) and III (moderate) heart failure based on the New York Heart Association classification scale and specialist physician approval
Age over 50 years
Minimum literacy
Living with family
The ability to use smartphones</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having psychological illnesses
Chronic diseases other than hypertension and diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Heart failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The educational intervention is designed based on the third phase of the Precede- Proceed Model, educational assessment, among the predisposing, enabling, and reinforcing constructs. Then, impact evaluation is carried out to examine the immediate effect of the program, including therapy adherence and readmission. Predisposing factors include the knowledge, attitudes, and beliefs of the affected person. Two 60-minute face-to-face sessions will be held to promote patients' awareness. In the first training session, we will discuss the following themes: familiarity of patients with adherence to treatment and medication, their knowledge about the benefits of treatment adherence and how to use medication, the definition of adherence to medication and therapy, and factors affecting these variables, appropriate dietary and lifestyle changes in heart failure according to the existing recommendations, and approaches to control these variables. There will be two 60-minute discussion sessions to assess patients' attitudes and provide the researcher's opinion to the participants. Reinforcing factors in this study include encouragement from the spouse or a family member (a key figure in a person's life). A 60-minute face-to-face meeting will be held with the key person to discuss the family's role in the disease process, encouragement strategies, and methods to motivate the patient. The enabling factors include two 60-minute training sessions to discuss the role of mass media in treatment adherence and the importance of quality of life improvement. Also, the authors will use a virtual social network. Finally, there will be a session to review the issues and resolve the problems and any ambiguities. Researchers will use PowerPoint slides and educational posters in all sessions. The intervention is performed for the experimental group in a month (two sessions per week). During this time, the intervention group will join a virtual educational channel, and the educational materials will be shared in this channel. Before and after the intervention, a demographic questionnaire, the Madanloo treatment adherence questionnaire, and a researcher-made readmission inventory will be completed. Post-test will be conducted one and three months after training, respectively.</i_keyword>
      <i_keyword>Control group: The control group will not receive any intervention and receive routine care.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of treatment adherence in madanloo questionnaire. Timepoint: Before study, One month after study and Three month after study. Method of measurement: Madanloo treatment adherence questionnaire.</prim_outcome>
      <prim_outcome>Percentage of people with readmission. Timepoint: One month after study and Three month after study. Method of measurement: Researcher-made questionnaire on readmission rate.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-07</approval_date>
        <contact_name>Ethics Committee of the School of Nursing and Midwifery and the School of Rehabilitation, Tehran Uni</contact_name>
        <contact_address>Tehran University of Medical Sciences., ghods Ave., Keshavarz BLvd., Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
